SCHEMBL13668378

SCHEMBL13668378

CC(/C=C(\NC(=O)c1ccccc1)C(=O)NCCOCCNC(=O)/C(=C/C(C)=C/c1ccc(N=[N+]=[N-])cc1)NC(=O)c1ccccc1)=C\c1ccc(N=[N+]=[N-])cc1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.46
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ KMT2A Q03164 8/20 0.41
▸ MEN1 O00255 5/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ SCN1A P35498 1/20 0.39
▸ SCN2A Q99250 1/20 0.39
▸ SCN3A Q9NY46 1/20 0.39
▸ MAPT P10636 3/20 0.38
▸ GAA P10253 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13668377 0.90 KMT2A (0.48) LMNACYP3A4CYP2C19SMN1; SMN2KMT2A
SCHEMBL13668375 0.89 RAB9A (0.46) LMNACYP3A4SMN1; SMN2KMT2AMEN1
SCHEMBL14340626 0.80 LMNA (0.35) LMNACYP3A4CYP2C19KMT2AMEN1
SCHEMBL16576002 0.79 KMT2A (0.46) LMNACYP3A4CYP2C19SMN1; SMN2KMT2A
SCHEMBL16575968 0.77 LMNA (0.47) LMNASMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL13668376 0.76 KDM4E (0.54) SMN1; SMN2KMT2AMEN1ALDH1A1GAA
SCHEMBL14340653 0.74 MEN1 (0.46) LMNACYP3A4CYP2C19SMN1; SMN2KMT2A
SCHEMBL23254715 0.70 SCN1A (0.61) SMN1; SMN2KMT2AALDH1A1SCN1ASCN2A
SCHEMBL24386187 0.69 SCN1A (0.60) SMN1; SMN2KMT2AALDH1A1SCN1ASCN2A
SCHEMBL23148219 0.69 SCN1A (0.59) LMNASMN1; SMN2KMT2AALDH1A1SCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605191-B2 polyoxyethylene glycol having end group of acrylamide derivatives, can be curing to provide medical device a surface coating which has hydrophilicity and high bioadaptability TOYO GOSEI CO., LTD. (JP) 2009-10-20 — — US disclosed
Send feedback